BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Eli Lilly's Mounjaro enters Indian market, triggering a sharp rise in consultations as obesity rates climb and patients seek more accessible treatment options ...

The maker of Ozempic and the weight loss drug Wegovy told the FDA on April 3 that counterfeit 1-milligram injections were ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

The maker of Ozempic and federal regulators are sending out warnings about counterfeit versions of the anti-diabetic drug ...

The maker of Ozempic and federal regulators are sending out warnings about counterfeit versions of the anti-diabetic drug ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...